Bio-Techne Corp (TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

• 年次報告書（10-K）

  事業内容、財務実績、リスクをまとめた年次の概要。

  提出日: 2026-08-24

  書類を見る

• 四半期報告書（10-Q）

  直近3か月間の業績に関する最新情報。

  提出日: 2026-05-06

  書類を見る

• 臨時報告書（8-K）

  経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

  提出日: 2026-09-23

  書類を見る

• 6/15/2026POSITIVE
  Activist Investor Ananym Urges Bio-Techne to Consider Selling

  Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.

• 3/13/2026NEGATIVE
  Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

  A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.